PCRX-201 became part of Pacira's portfolio in 2021, but was originally developed at Baylor and then by GQ Bio Therapeutics, ...

Ataraxis AI will use the new funding to bring to market its first offering, Ataraxis Breast, an AI-native prognostic/predictive platform for breast cancer.

Researchers are testing whether the Clarity ctDNA test can reliably identify patients who do just as well long term with less chemotherapy.

Troculeucel is an immunotherapeutic, in which a patient's autologous natural killer cells are expanded ex vivo. It is designed to reduce or prevent chronic neuroinflammation in patients who have ...